Denali Therapeutics Inc. financial data

Symbol
DNLI on Nasdaq
Location
161 Oyster Point Blvd., South San Francisco, CA
Fiscal year end
December 31
Latest financial report
10-Q - Q2 2025 - Aug 11, 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 953 % -29%
Debt-to-equity 12.1 % +25%
Return On Equity -40.8 % -21.3%
Return On Assets -36.4 % -18.7%
Operating Margin -65.5 % +83.2%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 146M shares +2.13%
Common Stock, Shares, Outstanding 146M shares +1.79%
Entity Public Float 1.9B USD -5%
Common Stock, Value, Issued 1.71M USD +1.48%
Weighted Average Number of Shares Outstanding, Basic 171M shares +1.55%
Weighted Average Number of Shares Outstanding, Diluted 171M shares +1.55%

Income Statement

Label TTM Value / Value Unit Change %
Revenues 295M USD +191%
Revenue from Contract with Customer, Excluding Assessed Tax 0 USD -100%
Research and Development Expense 417M USD +5.3%
General and Administrative Expense 117M USD +16%
Operating Income (Loss) -534M USD -11%
Nonoperating Income (Expense) 51.5M USD +249%
Income Tax Expense (Benefit) 0 USD
Net Income (Loss) Attributable to Parent -479M USD -14.2%
Earnings Per Share, Basic -2 USD/shares +2.44%
Earnings Per Share, Diluted -2 USD/shares +1.06%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 141M USD +89.1%
Marketable Securities, Current 758M USD -7.75%
Assets, Current 935M USD +0.68%
Property, Plant and Equipment, Net 58.7M USD +22.1%
Operating Lease, Right-of-Use Asset 21M USD -14.3%
Other Assets, Noncurrent 23M USD -54.6%
Assets 1.17B USD -22.4%
Accounts Payable, Current 10.8M USD -22.2%
Employee-related Liabilities, Current 12.1M USD +26.3%
Accrued Liabilities, Current 7.01M USD +16.5%
Contract with Customer, Liability, Current 0 USD -100%
Liabilities, Current 91.1M USD +22.2%
Contract with Customer, Liability, Noncurrent 0 USD -100%
Operating Lease, Liability, Noncurrent 32.1M USD -21.6%
Other Liabilities, Noncurrent 0 USD -100%
Liabilities 139M USD +20.5%
Accumulated Other Comprehensive Income (Loss), Net of Tax 939K USD
Retained Earnings (Accumulated Deficit) -1.8B USD -36.4%
Stockholders' Equity Attributable to Parent 1.03B USD -26%
Liabilities and Equity 1.17B USD -22.4%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -131M USD -15.7%
Net Cash Provided by (Used in) Financing Activities -3.76M USD -101%
Net Cash Provided by (Used in) Investing Activities 18.7M USD
Common Stock, Shares Authorized 400M shares 0%
Common Stock, Shares, Issued 146M shares +1.79%
Common Stock, Par or Stated Value Per Share 0.01 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -116M USD -75.1%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 144M USD +89.3%
Deferred Tax Assets, Valuation Allowance 488M USD +29.8%
Deferred Tax Assets, Gross 504M USD +30%
Operating Lease, Liability 41M USD -15.9%
Payments to Acquire Property, Plant, and Equipment 5.08M USD +136%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -475M USD -13%
Lessee, Operating Lease, Liability, to be Paid 48.1M USD -19.4%
Property, Plant and Equipment, Gross 107M USD +17.1%
Operating Lease, Liability, Current 8.87M USD +14.2%
Lessee, Operating Lease, Liability, to be Paid, Year Two 12.6M USD +3.3%
Lessee, Operating Lease, Liability, to be Paid, Year One 12.2M USD +3.3%
Operating Lease, Weighted Average Discount Rate, Percent 0.09 pure 0%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 7.13M USD -35%
Lessee, Operating Lease, Liability, to be Paid, Year Three 13M USD +3.31%
Deferred Tax Assets, Operating Loss Carryforwards 113M USD +27%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 40M shares 0%
Unrecognized Tax Benefits 33.8M USD +29%
Lessee, Operating Lease, Liability, to be Paid, Year Four 4.38M USD -66.3%
Operating Lease, Payments 11.6M USD +3.29%
Additional Paid in Capital 2.82B USD +4.27%
Preferred Stock, Shares Outstanding 0 shares
Depreciation, Depletion and Amortization 2.33M USD +7.54%
Deferred Tax Assets, Net of Valuation Allowance 16.3M USD +36.5%
Share-based Payment Arrangement, Expense 100M USD -5.55%
Preferred Stock, Par or Stated Value Per Share 0.01 USD/shares 0%